Abstract
Clinical trials have been used to assess the efficacy of therapeutic and preventive interventions in human subjects for more than two centuries. Clinical trial design, study implementation methods and analytical techniques have been refined progressively to make the clinical trial the `gold standard’ for both clinical and epidemiologic researchers. In transplantation, as well as in other fields, the criteria for a meaningful clinical trial are straightforward. We will briefly review these criteria as well as the current rationale of clinical trials in organ transplantation with a special reference to kidney transplantation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet. 1983; 2: 986–989.
European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995; 345: 1321–1325.
Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation. 1997; 64: 436–443.
Norman DJ, Kahana L, Stuart FP et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation. 1993; 55: 44–50.
Nashan B, Moore R, Amlot P et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 1997; 351: 1193–1198.
Yang HC, Holman MJ, Ulsh PJ et al. Tacrolimus Sow dose’/mycophenolate mofetil versus micro-emulsion cyclosporine/`low dose’ mycophenolate mofetil after kidney transplantation. One-year follow-up of a prospective randomized clinical trial. Am. Soc. Transpl. Phys., Chicago 1998, [abstract].
Krentz AJ, Dmitrewski J, Mayer D et al. Effects of immunosuppressive agents on glucose metabolism. Clin. Immunother. 1995; 4: 103–123.
Massy ZA, Kasiske BL. Post-transplant hyperlipidemia: mechanisms and management. J. Am. Soc. Nephrol. 1996; 7: 971–977
Massari PU. Disorders of bone and mineral metabolism after renal transplantation. Kidney Int. 1997; 52: 1412–1421.
Dimeny E, Fellström B. Metabolic abnormalities in renal transplant recipients. Risk factors and predictors of chronic graft dysfunction. Nephrol. Dial. Transplant. 1997; 12: 21–24.
Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998; 351: 623–628.
Monaco AP, Burke JF, Ferguson RM et al. Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1977 roundtable discussion. Am. J. Kidney Dis. 1999; 33: 150–160.
Mathew TH, for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term, randomized multicenter study of mycophenalate mofetil in cadaveric renal transplantation: results at 3 years. Transplantation. 1998; 65: 1450–1454.
Editor information
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Legendre, C. (1999). Rationale of clinical trials from the physician. In: Cochat, P., Traeger, J., Merieux, C., Derchavane, M. (eds) Immunosuppression under Trial. Transplantation and Clinical Immunology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4643-2_2
Download citation
DOI: https://doi.org/10.1007/978-94-011-4643-2_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5960-2
Online ISBN: 978-94-011-4643-2
eBook Packages: Springer Book Archive